Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Bronchiolitis Obliterans Syndrome × KD025 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

CRC 1 Bronchiolitis Obliterans Syndrome 1

Interventions

tofacitinib 7 ibrutinib 7 Imatinib Mesylate 4 Dasatinib 4 ruxolitinib 3 ofatumumab 3 nilotinib 3 fludarabine 3 bosutinib 3 Rituximab 3 Cyclophosphamide 3 obinutuzumab 2 asciminib 2 Sirolimus 2 Oxycodone 2 Naloxone 2 Mycophenolic Acid 2 KW-2478 2 Alemtuzumab 2 ziconotide 1 ponatinib 1 mocetinostat 1 milatuzumab 1 lonafarnib 1 fenebrutinib 1 canakinumab 1 belumosudil 1 baricitinib 1 axatilimab 1 abexinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03640481 2024-12-12

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Sanofi

Phase 2 Terminated

159 enrolled 25 charts 1 FDA

Bronchiolitis Obliterans Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡